# Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine

> **NCT05460377** · PHASE4 · COMPLETED · sponsor: **Centers for Disease Control and Prevention** · enrollment: 1224 (actual)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** Full dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS
- **BIOLOGICAL:** Fractional (1/5) Dose Sabin Inactivated Poliovirus Vaccine produced by IMBCAMS
- **BIOLOGICAL:** Full dose Sabin Inactivated Poliovirus Vaccine produced by BIBP
- **BIOLOGICAL:** Fractional (1/5) dose Sabin Inactivated Poliovirus Vaccine produced by BIBP

## Key facts

- **NCT ID:** NCT05460377
- **Lead sponsor:** Centers for Disease Control and Prevention
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-26
- **Primary completion:** 2023-07-22
- **Final completion:** 2024-12-01
- **Target enrollment:** 1224 (ACTUAL)
- **Last updated:** 2025-03-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05460377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05460377, "Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05460377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*